Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Predictors and GVL Effects of UCB Chimerism after Haplo-Cord Transplant

Nebu Koshy, MD, Sebastian A. Mayer, MD, Adrienne Phillips, MD, Rosanna Ferrante, CHTC, Ronit Slotky, PhD MSc, Usama Gergis, MD, Hanna Rennert, PhD, Melissa M. Cushing, MD, Tsiporah B. Shore, MD, Koen van Besien, MD

Blood (2015) 126 (23): 4385.

https://doi.org/10.1182/blood.V126.23.4385.4385

Published: 2015

Journal Articles

Refractory T-Cell Prolymphocytic Leukemia with JAK3 Mutation: In Vitro and Clinical Synergy of Tofacitinib and Ruxolitinib

Mike Wei, B.S., Nebu Koshy, MD, Koen van Besien, MD, Giorgio Inghirami, MD, Steven M. Horwitz, MD

Blood (2015) 126 (23): 5486.

https://doi.org/10.1182/blood.V126.23.5486.5486

Published: 2015

Journal Articles

Is Interim/Mid-Treatment PET (interim PET, i-PET) Scan Predictive of Outcome in Diffuse Large B-Cell Lymphoma?.

Dushyant Verma, MD, FACP, Amol Takalkar, MD, Runhua Shi, MD, PhD, Glenn M. Mills, MD, FACP, Srikanth Paladugu, MD, Diana Veillon, MD, Reinhold Munker, MD, Gerhard Hildebrandt, MD, Binu S. Nair, MD, FACP, Nebu Koshy, MD, FACP

Blood (2012) 120 (21): 2675.

https://doi.org/10.1182/blood.V120.21.2675.2675

Published: 2012

Journal Articles

A Randomized, Open-Label, Multicenter, Dose Escalation Study of HQK-1001 (2,2-Dimethylbutyrate, Sodium Salt) in Sickle Cell Disease

Abdullah Kutlar, MD, Marvin Reid, PhD, Ali T Taher, MD, Adlette Inati, MD, Miguel R. Abboud, MD, Amal El-Beshlawy, MD, George R. Buchanan, MD, Hedy Smith, MD PhD, Kenneth I. Ataga, MD, Nebu Koshy, MD, FACP, Lynne D Neumayr, MD, Punam Malik, M.D., Ofelia A. Alvarez, MD, Richard Ward, MBBS, MRCP, FRCPath, J Michael White, PhD, Elsa Johnson, MBA, Richard G. Ghalie, MD

Blood (2012) 120 (21): 998.

https://doi.org/10.1182/blood.V120.21.998.998

Published: 2012

Journal Articles

A Phase 2 Clinical Study of HQK-1001 (2,2-dimethylbutyrate, sodium salt), a Fetal Hemoglobin Inducer, in Patients with Sickle Cell Disease

Abdullah Kutlar, MD, Adlette Inati, MD, Ali T Taher, MD, Amal El-Beshlawy, MD, Marvin Reid, PhD, Miguel R. Abboud, MD, Hedy Smith, MD, PhD, Kenneth I. Ataga, MD, George R. Buchanan, MD, Punam Malik, MD, Nebu Koshy, MD, Lynne Neumayr, MD, Maria Aiello, MA, Elsa Johnson, MBA, J Michael White, PhD, Richard G. Ghalie, MD

Blood (2011) 118 (21): 1066.

https://doi.org/10.1182/blood.V118.21.1066.1066

Published: 2011

Journal Articles

Effect of Nilotinib (NIL) on Molecular Response in Chronic Myelogenous Leukemia - Chronic Phase (CML-CP) Patients (pts) with a Suboptimal Molecular Response to Imatinib (IM)–ENABL Study Update

Sikander Ailawadhi, MD, Carole B. Miller, MD, Anand P. Jillella, MD, Nebu Koshy, MD, Brian Tudor, MD, Luke P. Akard, MD, Solveig G. Ericson, MD- PhD, Felice P. Lin, PharmD, Jerald P. Radich, MD, Daniel J. DeAngelo, MD, PhD

Blood (2011) 118 (21): 2771.

https://doi.org/10.1182/blood.V118.21.2771.2771

Published: 2011

Journal Articles

Impact of Health Care Funding on overall Survival of Patients with Multiple Myeloma and Monoclonal Gammopathy of Uncertain Significance.

Srinivas S Devarakonda, MD, Binu S. Nair, MD, Ryan A. Gonzales, MD, Runhua Shi, MD, PhD, Nebu Koshy, MD, Gary Burton, MD, Jonathan Glass, MD, Francesco Turturro, MD

Blood (2010) 116 (21): 3821.

https://doi.org/10.1182/blood.V116.21.3821.3821

Published: 2010

NARROW

Predictors and GVL Effects of UCB Chimerism after Haplo-Cord Transplant

Refractory T-Cell Prolymphocytic Leukemia with JAK3 Mutation: In Vitro and Clinical Synergy of Tofacitinib and Ruxolitinib

Is Interim/Mid-Treatment PET (interim PET, i-PET) Scan Predictive of Outcome in Diffuse Large B-Cell Lymphoma?.

A Randomized, Open-Label, Multicenter, Dose Escalation Study of HQK-1001 (2,2-Dimethylbutyrate, Sodium Salt) in Sickle Cell Disease

A Phase 2 Clinical Study of HQK-1001 (2,2-dimethylbutyrate, sodium salt), a Fetal Hemoglobin Inducer, in Patients with Sickle Cell Disease

Effect of Nilotinib (NIL) on Molecular Response in Chronic Myelogenous Leukemia - Chronic Phase (CML-CP) Patients (pts) with a Suboptimal Molecular Response to Imatinib (IM)–ENABL Study Update

Impact of Health Care Funding on overall Survival of Patients with Multiple Myeloma and Monoclonal Gammopathy of Uncertain Significance.

Email alerts

ASH Publications

American Society of Hematology

Predictors and GVL Effects of UCB Chimerism after Haplo-Cord Transplant

Refractory T-Cell Prolymphocytic Leukemia with JAK3 Mutation: In Vitro and Clinical Synergy of Tofacitinib and Ruxolitinib

Is Interim/Mid-Treatment PET (interim PET, i-PET) Scan Predictive of Outcome in Diffuse Large B-Cell Lymphoma?.

A Randomized, Open-Label, Multicenter, Dose Escalation Study of HQK-1001 (2,2-Dimethylbutyrate, Sodium Salt) in Sickle Cell Disease

A Phase 2 Clinical Study of HQK-1001 (2,2-dimethylbutyrate, sodium salt), a Fetal Hemoglobin Inducer, in Patients with Sickle Cell Disease

Effect of Nilotinib (NIL) on Molecular Response in Chronic Myelogenous Leukemia - Chronic Phase (CML-CP) Patients (pts) with a Suboptimal Molecular Response to Imatinib (IM)–ENABL Study Update

Impact of Health Care Funding on overall Survival of Patients with Multiple Myeloma and Monoclonal Gammopathy of Uncertain Significance.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only